Bradbury Melissa, Borràs Eva, Pérez-Benavente Assumpció, Gil-Moreno Antonio, Santamaria Anna, Sabidó Eduard
Centre de Regulació Genòmica, Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, 08003 Barcelona, Spain.
Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr Aiguader 88, 08003 Barcelona, Spain.
Cancers (Basel). 2021 Apr 25;13(9):2067. doi: 10.3390/cancers13092067.
High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.
高级别浆液性卵巢癌（HGSC）仍然是卵巢癌最常见且致命的亚型。其特征在于尽管采用了减瘤手术和铂类化疗的标准化治疗，但仍诊断较晚且频繁复发。在《癌症基因组图谱》（TCGA）研究人员发表研究成果以及在特定亚组患者中引入抗血管生成药物和聚（ADP - 核糖）聚合酶抑制剂等靶向治疗方法之后，过去十年里高级别浆液性卵巢癌的临床管理和分子认识取得了重大进展。我们对高级别浆液性卵巢癌进行了全面综述，重点关注最重要的分子进展，旨在更好地理解该疾病及其对治疗的反应。我们强调蛋白质组学技术目前在该疾病的这两个方面所发挥的作用，即通过鉴定卵巢癌肿瘤中的蛋白质及其翻译后修饰。最后，我们突出了以临床蛋白质组肿瘤分析联盟（CPTAC）所开展的工作为例的蛋白质组学与基因组学的整合如何能够指导新生物标志物和治疗靶点的开发。
